Funding agencies: This study was supported by an unrestricted research grant from Kyowa Hakko Kirin, Co. Ltd., Tokyo, Japan.
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Article first published online: 11 MAR 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 8, pages 1138–1141, July 2013
How to Cite
Mizuno, Y., Kondo, T. and the Japanese Istradefylline Study Group (2013), Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov. Disord., 28: 1138–1141. doi: 10.1002/mds.25418
This study was supported by Kyowa Hakko Kirin Co., Ltd., Japan.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the Acknowledgments section online.
- Issue published online: 12 AUG 2013
- Article first published online: 11 MAR 2013
- Manuscript Accepted: 28 JAN 2013
- Manuscript Revised: 24 JAN 2013
- Manuscript Received: 6 NOV 2012
- Parkinson's disease;
- motor complications;
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. © 2013 Movement Disorder Society